- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04384614
Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study (CONNAITRE)
August 25, 2020 updated by: Agnès Hamzaoui, Direction des Soins de Santé de Base
Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study Multicentric Study
Covid-19 In Tunisia: AN Observational Cross-Sectional Registry Study
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tunis, Tunisia
- Eshmoun Clinical Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 76 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
400 Patients will be included between COVID19 (+) and COVID19 (-) patients who have been in contact with COVID19 (+)
Description
Inclusion Criteria:
- COVID-19 (+), inpatient or outpatient, confirmed by PCR test
- COVID-19 (-) confirmed by PCR test having been in contact with COVID-19 (+)
Exclusion Criteria:
- COVID(+) and COVID(-) diagnosed by other tests than PCR
- COVID-19 (-) Not having been in contact with COVID19(+)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
COVID (+)
Patients COVID19(+) confirmed by PCR
|
Viral load (COVID+) testing by PCR
IDR and blood sampling for testing DNA Cheque
COVID 19 symptoms and Physical Examination
|
|
COVID (-)
Patients COVID19 (-) who had been in contact with COVID-19 (+) confirmed by PCR
|
Viral load (COVID+) testing by PCR
IDR and blood sampling for testing DNA Cheque
COVID 19 symptoms and Physical Examination
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences related to epidemiological demographic characteristics
Time Frame: 30 days
|
Identify differences related to epidemiological demographic characteristics and the profile of COVID(+) vs. the profile of COVID(-) patients who have been in contact with COVID(+)
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Agnès Hamzaoui, Pr, Hopital Abderrahmane Mami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 15, 2020
Primary Completion (Anticipated)
July 15, 2020
Study Completion (Anticipated)
July 15, 2020
Study Registration Dates
First Submitted
May 9, 2020
First Submitted That Met QC Criteria
May 9, 2020
First Posted (Actual)
May 12, 2020
Study Record Updates
Last Update Posted (Actual)
August 27, 2020
Last Update Submitted That Met QC Criteria
August 25, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECC2020-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid 19
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)Germany
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
ModeX Therapeutics, An OPKO Health CompanyRecruitingCOVID -19 | COVID-19 (Prevention)United States
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID ConditionCanada
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
Clinical Trials on Test PCR
-
QuantuMDx Group LtdPathAI; Bright Research Center; New Day DiagnosticsCompleted
-
American Burn AssociationU.S. Army Medical Research and Development CommandCompleted
-
IgenomixUnknown
-
University Medical Centre LjubljanaCompletedRespiratory Viral Infections | Multiple Mieloma
-
University of Southern DenmarkRoche Diagnostics GmbHActive, not recruitingRespiratory Tract InfectionsDenmark
-
King's College LondonZoe Global Limited; Department of Health, United KingdomRecruiting
-
CMC Ambroise ParéTerminatedCOVID-19 | SARS-CoV-2France
-
Aarhus University HospitalWithdrawnStroke, Acute | Seizure Disorder | Neurological Diseases or ConditionsDenmark
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingHelicobacter Pylori InfectionChina
-
Cairo UniversityCompleted